GlaxoSmithKline Gets Positive Results From Phase III Studies For Mepolizumab
LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, has met its primary endpoint of reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma. The study e Read More